Abstract. Tumor protein 53 (TP53), a tumor suppressor gene, is a vital cellular cancer suppressor in multicellular organisms. Murine double minute-2 (MDM2) is an oncoprotein that inhibits TP53 activity. A number of studies have examined the association of TP53 and MDM2 polymorphisms with the risk of common forms of cancer, but the findings remain inconclusive. The present study aimed to evaluate the impact of the 40-bp insertion/deletion (I/D) polymorphism (rs3730485) in the MDM2 promoter region and the 16-bp I/D polymorphism (rs17878362) in TP53 on the susceptibility of prostate cancer (PCa) in a sample of the Iranian population. This case-control study included 103 patients with pathologically confirmed PCa and 142 patients with benign prostatic hyperplasia. The 
Introduction
Prostate cancer (PCa) is the most prevalent form of cancer among males in the United States (1). In Iran, the incidence of PCa is ~9.6 cases per 100,000 individuals, with a range of 3.2-16.0 per 100,000 in various geographical settings (2, 3) . This is comparable with the Asia-Pacific region (9.9 per 100,000), but significantly lower than in the rest of the world (32.8 per 100,000) (4). The median age at diagnosis is ~66 years and the 5-year survival rate of patients with PCa has been estimated to be 98.9% (5) .
The molecular mechanisms underlying the progression and carcinogenesis of PCa have not yet been clarified. Additional molecular markers that may be employed to detect PCa and to individualize patient therapy and prognosis are of great clinical importance. A number of large cohort and case-control studies with various populations suggest that family history is a primary risk factor for PCa (6) (7) (8) (9) (10) .
In humans, the tumor protein 53 (TP53) gene is located on the short arm of chromosome 17 (17p13.1) (11) . TP53, an important tumor suppressor gene, is a crucial regulator of apoptosis and the cell cycle (12) (13) (14) (15) . When it is mutated, this regulation may be lost, leading to uncontrolled cell proliferation and potentially tumorigenesis (16) .
The human MDM2 gene is mapped on chromosome 12q14. 3-15 (17) . MDM2 functions as a key negative regulator of TP53 (18) , inhibiting the transcriptional activity of TP53 and enhancing proteolytic P53 degradation (19) . (20) (21) (22) (23) (24) (25) (26) (27) (28) . Therefore, the current study aimed to determine the possible association of the 16-bp I/D polymorphism within intron 3 of TP53 and the 40-bp I/D polymorphism in the promoter region of MDM2 with PCa in a sample of an Iranian population.
Materials and methods
Patients. The present case-control study enrolled 103 histopathologically-confirmed patients with PCa and 142 age-matched men with benign prostatic hyperplasia (BPH), who had been referred to the Department of Urology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences (Tehran, Iran). The enrollment process and study design were performed as previously described (29) . Ethical approval for the study was obtained from the Ethics Committee of Zahedan University of Medical Sciences, and written informed consent was obtained from all participating patients. Blood samples were collected in EDTA-containing tubes from patients and controls, and DNA was extracted using the salting out method as previously described (30) .
Genotyping. MDM2 40-bp I/D polymorphism genotyping was performed using forward (5'-GAC CAC TAT GTT TAA GGA AG-3') and reverse (5'-TGA CTC ACC TAC TTT CCC AC-3') primers, as described previously (28) . Polymerase chain reaction (PCR) was performed using commercially available Prime Taq Premix (Genet Bio, Daejeon, South Korea), according to the manufacturer's recommended protocol. The PCR cycling conditions were as follows: An initial denaturation at 95˚C for 5 min, followed by 30 cycles at 95˚C for 30 sec, 59˚C for 25 sec, 72˚C for 30 sec and a final extension step at 72˚C for 10 min. The product sizes for the I and D alleles were 287 and 247 bp, respectively. The PCR products were verified using 2.5% agarose gels containing 0.5 µg/ml ethidium bromide, and observed under UV light (Fig. 1) . Genotyping of the 16-bp duplication polymorphism in TP53 was performed by PCR using forward (5'-CTG AAA ACA ACG TTC TGG TA-3') and reverse (5'-AAG GGG GAC TGT AGA TGG GTG-3') primers (31) as previously described (32) . The PCR conditions were as follows: An initial denaturation step at 95˚C for 5 min, followed by 30 cycles at 95˚C for 30 sec, 60˚C for 30 sec and 72˚C for 30 sec, with a final extension step at 72˚C for 10 min. The TP53 wild type allele, the D allele (no duplication), resulted in a 119-bp fragment and the variant alleles, the I allele (with 16-bp duplication), resulted in a 135-bp fragment (Fig. 2) . Approximately 15% of the samples were randomly selected for confirmation and the results were all consistent.
Statistical analysis. Statistical analysis was performed using SPSS v18 (SPSS, Inc., Chicago, IL, USA). Continuous and categorical data were analyzed using the independent sample t-test and the χ 2 test, respectively. Associations of the MDM2 40-bp I/D and the TP53 16-bp I/D polymorphism with PCa were calculated by computing the odds ratio (OR) and 95% confidence intervals (95% CIs) from logistic regression analyses. The genotype distribution of variants was tested for Hardy-Weinberg equilibrium (HWE) separately for cases and controls. P<0.05 was considered to indicate a statistically significant difference.
Results

Patient characteristics.
In total, 103 patients with PCa were enrolled with a mean age of 61.03±6.03 years, and 142 patients with BPH (control group) were enrolled with a mean age of 62.57±7.85 years. No significant difference in age was observed between the groups (P=0.097). The clinicopathological characteristics of the patients with PCa are summarized in Table I The TP53 gene is a key tumor suppressor that encodes a 53-kDa protein, which is essential in DNA repair, cell cycle arrest and apoptosis in response to DNA damage (12) (13) (14) (15) 26, 36) . TP53 mutations are the most frequent gene mutations in the majority of types of human cancer, and they permit cells to proliferate and survive (37) . Rapid phosphorylation of TP53 by ataxia telangiectasia mutated (ATM) following DNA damage leads to increased TP53 stability and activity (38, 39) . TP53-induced gene expression leads to cell cycle arrest and apoptosis (40) . When TP53 is mutated, this effect may be lost, resulting in uncontrolled cell proliferation that may result in tumorigenesis (16) . It has been proposed that genetic polymorphisms in TP53 may affect a number of its functions (41) .
MDM2, a key negative regulator of TP53, is able to bind directly to TP53 and inhibit its transcriptional activity (18) . MDM2 also promotes the ubiquitination and subsequent degradation of TP53 (19, 42) . Promoter polymorphisms in the MDM2 gene may affect MDM2 cellular protein levels (43) , and MDM2 overexpression has been reported in several forms of human cancer (44) (45) (46) .
In agreement with the results of the present study, Mittal et al (47) The intron sequences in TP53 are involved in regulating gene expression and in DNA-protein interactions (56, 57) . It has been proposed that the TP53 intron 3 16-bp I variant is associated with lower levels of TP53 transcripts, which suggests that this duplication polymorphism causes an alteration in mRNA processing and may be a risk factor for developing cancer (57) . In addition, it has been suggested that the TP53 codon 72 variant may be a low-penetrant risk factor for developing PCa in Caucasians, but not in Asians (58) , and variants within the TP53 binding sites may be valuable biomarkers for the prognosis of patients with PCa (59) .
The current study observed that the 40-bp I/D polymorphism in the MDM2 promoter increased the risk of PCa. A recent study reported that the MDM2 40-bp I/D variant increased the risk of breast cancer in an Iranian population (28) . Furthermore, a significant association between MDM2 I/D and lung cancer was detected in the Chinese population (26) . In addition, the MDM2 40-bp I/D variant has been demonstrated to be a risk factor for hepatocellular carcinoma in the Chinese population (25) . By contrast, no association was identified between the MDM2 40-bp I/D polymorphism and breast cancer in the Chinese population (27) .
The limitations of the present study are as follows: Firstly, relatively small sample sizes were used, therefore repetition with larger samples is required; secondly, gene-environment interactions were not determined. It has been proposed that environmental and genetic factors each serve a role in PCa development. In conclusion, the results of the present study 
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